- Home
- HWH vs CLDI Comparison
HWH vs CLDI Comparison
Compare HWH & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWH
- CLDI
- Stock Information
- Founded
- HWH 2021
- CLDI 2014
- Country
- HWH United States
- CLDI United States
- Employees
- HWH N/A
- CLDI N/A
- Industry
- HWH Other Pharmaceuticals
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HWH Health Care
- CLDI Health Care
- Exchange
- HWH Nasdaq
- CLDI Nasdaq
- Market Cap
- HWH 10.1M
- CLDI 8.7M
- IPO Year
- HWH N/A
- CLDI N/A
- Fundamental
- Price
- HWH $2.75
- CLDI $1.60
- Analyst Decision
- HWH
- CLDI
- Analyst Count
- HWH 0
- CLDI 0
- Target Price
- HWH N/A
- CLDI N/A
- AVG Volume (30 Days)
- HWH 158.2K
- CLDI 141.6K
- Earning Date
- HWH 11-11-2025
- CLDI 11-11-2025
- Dividend Yield
- HWH N/A
- CLDI N/A
- EPS Growth
- HWH N/A
- CLDI N/A
- EPS
- HWH N/A
- CLDI N/A
- Revenue
- HWH $1,238,173.00
- CLDI N/A
- Revenue This Year
- HWH N/A
- CLDI N/A
- Revenue Next Year
- HWH N/A
- CLDI N/A
- P/E Ratio
- HWH N/A
- CLDI N/A
- Revenue Growth
- HWH 17.28
- CLDI N/A
- 52 Week Low
- HWH $0.90
- CLDI $1.41
- 52 Week High
- HWH $7.77
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- HWH 48.54
- CLDI 43.90
- Support Level
- HWH $2.66
- CLDI $1.41
- Resistance Level
- HWH $3.12
- CLDI $1.68
- Average True Range (ATR)
- HWH 0.19
- CLDI 0.08
- MACD
- HWH -0.06
- CLDI 0.05
- Stochastic Oscillator
- HWH 25.00
- CLDI 66.74
About HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.